Monday, 8 September 2008

Link Between Obesity, Type 2 Diabetes And Neurodegeneration

�New research from Rhode Island Hospital found that obesity and Type 2 Diabetes Mellitus (T2DM) can contribute to mild neurodegeneration with features common with Alzheimer's disease (AD) - the first gear study to show that obesity stern cause neurodegeneration. The study appeared in the Journal of Alzheimer's Disease Volume 15:1 (September 2008) .



In a study on animal models, lead researcher Suzanne de la Monte, MD, MPH, of Rhode Island Hospital, utilized chronic high fatty diets to cause a two-fold increment in hateful body weight unit. In these animal models, there was a marginally reduced mean brain weight and a significantly reduced mean brain weight/body weight ratio, providing evidence that obesity with T2DM is sufficient to cause mild global atrophy in the brain.



De la Monte says, "In nub, the psyche shrinks and several biochemical and molecular abnormalities establish in patients with AD, including brain insulin resistivity, develop with chronic fleshiness and T2DM. However, the extent of the abnormalities in no way matches AD." Researchers note that the neuropathological abnormalities were mild and the associated brain insulin resistance could serve as a co-factor in the development and progression of AD.



Overall, the study establish that that the personal effects of corpulency and T2DM can fundamentally aggravate or contribute to the severity or patterned advance of AD, but cannot be the sole suit of the condition. The findings suggest that strategies to deoxidise obesity and prevent or control T2DM could modify the clinical course of mild cognitive impairment and AD.



De la Monte likewise notes, "We don't know yet if these personal effects of T2DM/obesity are reversible with free weight loss. However, we're fair sure that the abnormalities are related to to the T2DM that accompanies obesity and not just increased weight."





The entire study is available at http://www.j-alz.com/.



Founded in 1863, Rhode Island Hospital (http://www.rhodeislandhospital.org/) is a private, not-for-profit hospital and is the largest instruction hospital of the Warren Alpert Medical School of Brown University. A major trauma centre for southeasterly New England, the infirmary is dedicated to being on the cutting border of practice of medicine and research. Rhode Island Hospital ranks among the country's starring independent hospitals that receive funding from the National Institutes of Health, with research awards of nearly $27 trillion annually. Many of its physicians are recognized as leaders in their several fields of cancer, cardiology, diabetes, clinical neurology, orthopedics and minimally invasive surgery. The hospital's pedology division, Hasbro Children's Hospital, has pioneered numerous procedures and is at the forefront of fetal surgical operation, orthopedics and pediatric neurosurgery. Rhode Island Hospital is a innovation member of the Lifespan health system.



Moroz, N. et al. (2008). Limited Alzheimer-Type Neurodegeneration in Experimental Obesity and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease. 15(1), 29-44.



The Journal of Alzheimer's Disease (http://www.j-alz.com/) is an international multidisciplinary journal to facilitate progression in discernment the aetiology, pathogenesis, epidemiology, genetics, behaviour, treatment and psychology of Alzheimer's disease. The daybook publishes enquiry reports, reviews, short communication theory, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the daybook includes novel therapeutic targets, mechanisms of disease and clinical visitation outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 4.081 according to Thomson Reuter's 2007 Journal Citation Reports. It is promulgated by IOS Press.



Source: Nancy Cawley

Lifespan



More info